MRD Response-adapted Allo-HSCT for Adverse-risk AML
MRD Response-adapted Allo-HSCT for Adverse-risk AML
Recruiting · NCT06301425 · Registry updated 2024-07-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| MRD Response-adapted Allo-HSCT for Adverse-risk AML | Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Not applicable | 2024-07-10 | NCT06301425 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Anhui Provincial Hospital | 101 |
| Peking University People's Hospital | 269 |
| Ruijin Hospital | 454 |
| Wuhan TongJi Hospital | 29 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Peking University People's Hospital | Beijing | China | 68 |